CoChat

Characterisation of premature cell senescence in Alzheimer's disease using single nuclear transcriptomics

Open access

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index; 46 of the 56 sources its claims cite were checked for support.

Abstract

Abstract Aging is associated with cell senescence and is the major risk factor for AD. We characterized premature cell senescence in postmortem brains from non-diseased controls (NDC) and donors with Alzheimer’s disease (AD) using imaging mass cytometry (IMC) and single nuclear RNA (snRNA) sequencing (> 200,000 nuclei). We found increases in numbers of glia immunostaining for galactosidase beta (> fourfold) and p16 INK4A (up to twofold) with AD relative to NDC. Increased glial expression of genes related to senescence was associated with greater β-amyloid load. Prematurely senescent microglia downregulated phagocytic pathways suggesting reduced capacity for β-amyloid clearance. Gene set enrichment and pseudo-time trajectories described extensive DNA double-strand breaks (DSBs), mitochondrial dysfunction and ER stress associated with increased β-amyloid leading to premature senescence in microglia. We replicated these observations with independent AD snRNA-seq datasets. Our results describe a burden of senescent glia with AD that is sufficiently high to contribute to disease progression. These findings support the hypothesis that microglia are a primary target for senolytic treatments in AD.

Overview

CoChat Summary

## TL;DR

The study used imaging mass cytometry and snRNA-seq on postmortem human cortex to characterize premature cell senescence in Alzheimer’s disease, finding the strongest senescence signature in microglia. The senescence burden tracked with β-amyloid pathology, with microglia showing reduced phagocytic pathways and evidence for DNA damage, mitochondrial dysfunction, and ER stress.

## Key findings

  • In cohort 1 IMC (10 AD vs 10 NDC, middle temporal gyrus), AD tissue had 4.1-fold more GLB1+ microglia, 4.6-fold more GLB1+ oligodendrocytes, and 4-fold more GLB1+ astrocytes than NDC; p16+ microglia increased 1.6-fold in AD.
  • In the snRNA-seq dataset, 203,970 nuclei from seven major brain cell types were analyzed; only microglia showed a significant increase in the canonical senescence pathway (CSP) in AD relative to NDC (Wilcoxon p = 0.0087).
  • Microglial senescence was linked to β-amyloid: more than 25% of microglia within 10 μm of plaques expressed GLB1, versus 3% of microglia >10 μm from plaques.
  • In AD, microglia upregulated DNA damage response and senescence-related genes, while phagocytosis-related pathways were downregulated; the paper also reports replication in independent snRNA-seq datasets and a meta-analysis across 14 datasets, with CSP upregulated in microglia in 12/14 datasets (p = 7e-04).

## Methods

  • Postmortem cortical tissue from NDC and AD donors was studied with IMC and snRNA-seq. Cohort 1: 10 NDC and 10 AD donors from MTG; Cohort 2: 8 NDC and 9 AD donors, with 49 brain samples across EC, MTG, and SSC.
  • snRNA-seq data were QC-filtered, integrated with LIGER, clustered, and annotated using EWCE against a human brain reference; senescence signatures were assessed with differential expression, gene set enrichment, pseudo-time, and mixed-model regression against β-amyloid.
  • IMC was analyzed by co-localization and automated image pipelines; senescent nuclei proportions were compared with Wilcoxon rank-sum tests, and transcriptomic associations used MAST mixed models and gene set analyses.

## Limitations

  • The paper states that it measures markers associated with senescence rather than direct evidence of permanent growth arrest.
  • Because the study is cross-sectional, the authors say dynamic senescence processes may be biased, likely toward underestimating senescent cell burden.
  • The authors note limited age range in the donor population and that the three sampled regions per brain are not fully independent, which limits confidence in some single-gene findings.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00401-024-02727-9

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Numbers of senescent glial cells are increased in brains of AD compared to those from NDC donors. (a, b: IMC data from cohort-1) a Multiplexed imaging mass cytometry (IMC) (scale bar = 50 µm) revealed overlapping expression of senescence (GLB1 and p16) and cell type specific markers (Iba1; microglia, OLIG2; oligodendrocyte lineage, GFAP; astrocyte) in cohort-1. b Proportions of GLB1+, p16+ and GLB1+p16+ microglia (Iba1+), oligodendrocyte (OLIG2+) and astrocyte (GFAP+) were calculated in AD and NDC using cohort-1 IMC data (Wilcoxon rank-sum test, *p ≤ 0.05. **p ≤ 0.01). (c–e: IMC data from cohort-2) c UMAP showing the cellular clusters generated by SIMPLI from cohort-2 IMC data. d Marker mean expression heatmap by clusters. e Proportion of nuclei of all clusters expressing senescence markers in AD and NDC (Wilcoxon rank-sum test, p ≤ 0.1 is reported)
Fig. 1 Numbers of senescent glial cells are increased in brains of AD compared to those from NDC donors. (a, b: IMC data from cohort-1) a Multiplexed imaging mass cytometry (IMC) (scale bar = 50 µm) revealed overlapping expression of senescence (GLB1 and p16) and cell type specific markers (Iba1; microglia, OLIG2; oligodendrocyte lineage, GFAP; astrocyte) in cohort-1. b Proportions of GLB1+, p16+ and GLB1+p16+ microglia (Iba1+), oligodendrocyte (OLIG2+) and astrocyte (GFAP+) were calculated in AD and NDC using cohort-1 IMC data (Wilcoxon rank-sum test, *p ≤ 0.05. **p ≤ 0.01). (c–e: IMC data from cohort-2) c UMAP showing the cellular clusters generated by SIMPLI from cohort-2 IMC data. d Marker mean expression heatmap by clusters. e Proportion of nuclei of all clusters expressing senescence markers in AD and NDC (Wilcoxon rank-sum test, p ≤ 0.1 is reported)CC BY · PubMed Central
Fig. 2 The microglial transcriptome is enriched for senescence gene expression in AD. a Study design showing the three regions from each of the 17 brains from which nuclei were isolated to generate snRNAseq data. b UMAP of seven distinct cell type populations characterized from snRNAseq data generated from 49 brain blocks. c Dot plot showing average scaled expression of genes and percentage of cells expressed from the ‘canonical senescence pathway (CSP)’, the ‘senescence initiating pathway (SIP)’ [16] and a custom senescence set (Supplementary data S5) for each cell type. d Normalised aggregated expression of genes as in (c) projected on UMAP. Color gradient scale showing aggregated gene set score in each nuclei. e Box plot showing scaled mean expression of the CSP genes in each cell type (Wilcoxon rank-sum test). f Percentage of senescent nuclei between AD and NDC across all cell types stratified by brain regions (Wilcoxon rank-sum test, *p ≤ 0.05) (Astro, astrocytes; Micro, microglia; Oligo, oligodendrocytes; OPC, Oligodendrocyte progenitor cells; Vasc, vascular cells; Exc, excitatory neurons, Inh; inhibitory neurons)
Fig. 2 The microglial transcriptome is enriched for senescence gene expression in AD. a Study design showing the three regions from each of the 17 brains from which nuclei were isolated to generate snRNAseq data. b UMAP of seven distinct cell type populations characterized from snRNAseq data generated from 49 brain blocks. c Dot plot showing average scaled expression of genes and percentage of cells expressed from the ‘canonical senescence pathway (CSP)’, the ‘senescence initiating pathway (SIP)’ [16] and a custom senescence set (Supplementary data S5) for each cell type. d Normalised aggregated expression of genes as in (c) projected on UMAP. Color gradient scale showing aggregated gene set score in each nuclei. e Box plot showing scaled mean expression of the CSP genes in each cell type (Wilcoxon rank-sum test). f Percentage of senescent nuclei between AD and NDC across all cell types stratified by brain regions (Wilcoxon rank-sum test, *p ≤ 0.05) (Astro, astrocytes; Micro, microglia; Oligo, oligodendrocytes; OPC, Oligodendrocyte progenitor cells; Vasc, vascular cells; Exc, excitatory neurons, Inh; inhibitory neurons)CC BY · PubMed Central
Fig. 3 Senescence-associated genes are differentially expressed in microglia from AD and NDC donors. a Volcano plot showing differentially expressed genes between AD and NDC in microglia; senescence genes are annotated in blue. Barplots showing up- b and down-regulated c gene pathway enrichments in microglia with AD relative to NDC. d Heatmap showing senescence and other relevant gene set enrichments in AD relative to NDC (adjusted p, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001)
Fig. 3 Senescence-associated genes are differentially expressed in microglia from AD and NDC donors. a Volcano plot showing differentially expressed genes between AD and NDC in microglia; senescence genes are annotated in blue. Barplots showing up- b and down-regulated c gene pathway enrichments in microglia with AD relative to NDC. d Heatmap showing senescence and other relevant gene set enrichments in AD relative to NDC (adjusted p, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001)CC BY · PubMed Central
Fig. 4 Senescence-associated genes are differentially expressed in microglia from AD and NDC donors. a IMC data (cohort-1) were used to quantify the number of cells positive for senescence markers GLB1, p16 or both by co-localizing them with the microglia marker Iba1 and 4G8+ β-amyloid plaque (yellow pixels). i and ii shows two plaque regions containing Iba1+positive cells. Iba1+ microglia within 10 μm of plaques were defined as peri-plaque microglia. b The proportion of peri-plaque microglia expressing senescence markers was significantly higher than for non-plaque microglia in AD (Wilcoxon rank-sum test, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). c Heatmap showing top 5 differentially expressed genes by logFC (adjusted p value 0.05) against β-amyloid loads measured by 4G8+ immunohistochemical staining densities in all cell types in snRNAseq data. d The gene expression graph illustrates its correlation with β-amyloid (4G8+) densities. The upper section displays the log2-normalized expression of each gene in individual nuclei, with median expression denoted by a black circle. The lower section indicates the percentage of non-zero nuclei in each sample
Fig. 4 Senescence-associated genes are differentially expressed in microglia from AD and NDC donors. a IMC data (cohort-1) were used to quantify the number of cells positive for senescence markers GLB1, p16 or both by co-localizing them with the microglia marker Iba1 and 4G8+ β-amyloid plaque (yellow pixels). i and ii shows two plaque regions containing Iba1+positive cells. Iba1+ microglia within 10 μm of plaques were defined as peri-plaque microglia. b The proportion of peri-plaque microglia expressing senescence markers was significantly higher than for non-plaque microglia in AD (Wilcoxon rank-sum test, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). c Heatmap showing top 5 differentially expressed genes by logFC (adjusted p value 0.05) against β-amyloid loads measured by 4G8+ immunohistochemical staining densities in all cell types in snRNAseq data. d The gene expression graph illustrates its correlation with β-amyloid (4G8+) densities. The upper section displays the log2-normalized expression of each gene in individual nuclei, with median expression denoted by a black circle. The lower section indicates the percentage of non-zero nuclei in each sampleCC BY · PubMed Central
Fig. 5 Sub-populations of microglia differentially express senescence gene signatures. a UMAP dimensionality reduction plot showing microglial sub-populations b Odds-ratio estimates of microglial sub-populations associated with AD (circle; OR estimate obtained from MASC [22], bars; 95% CI). c Differences in relative numbers of each of the microglial sub-populations isolated from AD and NDC cortical brain tissue. d Percentages of microglial sub-populations as a function of β-amyloid (4G8+) load (Micro2 Pearson’s R = 0.63, p value = 1.4e−06). e Boxplot showing normalised mean expression of the CSP gene set in the different microglial sub-populations (Wilcoxon rank-sum test). f Bar plots comparing the proportions of senescent nuclei between AD and Control for Micro1-3 (Wilcoxon test, **p value<0.01). g Correlations of the proportions of Micro1-3 senescent nuclei with β-amyloid (4G8+) immunostained areas in sampled region of each brain (Micro1 Pearson’s R = 0.34, p value = 0.021). h Boxplots showing the scaled mean expression of CSP gene set across microglial sub-population grouped by TREM2 genotype (CV, common allele, or the R47H AD risk variant)
Fig. 5 Sub-populations of microglia differentially express senescence gene signatures. a UMAP dimensionality reduction plot showing microglial sub-populations b Odds-ratio estimates of microglial sub-populations associated with AD (circle; OR estimate obtained from MASC [22], bars; 95% CI). c Differences in relative numbers of each of the microglial sub-populations isolated from AD and NDC cortical brain tissue. d Percentages of microglial sub-populations as a function of β-amyloid (4G8+) load (Micro2 Pearson’s R = 0.63, p value = 1.4e−06). e Boxplot showing normalised mean expression of the CSP gene set in the different microglial sub-populations (Wilcoxon rank-sum test). f Bar plots comparing the proportions of senescent nuclei between AD and Control for Micro1-3 (Wilcoxon test, **p value<0.01). g Correlations of the proportions of Micro1-3 senescent nuclei with β-amyloid (4G8+) immunostained areas in sampled region of each brain (Micro1 Pearson’s R = 0.34, p value = 0.021). h Boxplots showing the scaled mean expression of CSP gene set across microglial sub-population grouped by TREM2 genotype (CV, common allele, or the R47H AD risk variant)CC BY · PubMed Central
Fig. 6 Sub-clustering of oligodendrocytes and astrocytes. Sub-clustering of oligodendrocytes a, b and astrocytes c, d show diverse functional sub-populations. UMAP dimensionality reduction plots describing these sub-populations for oligodendroglia (a) and astrocytes (c). Normalised mean expression of CSP between AD and Control across sub-populations of oligodendrocytes (b) and astrocytes (d)
Fig. 6 Sub-clustering of oligodendrocytes and astrocytes. Sub-clustering of oligodendrocytes a, b and astrocytes c, d show diverse functional sub-populations. UMAP dimensionality reduction plots describing these sub-populations for oligodendroglia (a) and astrocytes (c). Normalised mean expression of CSP between AD and Control across sub-populations of oligodendrocytes (b) and astrocytes (d)CC BY · PubMed Central
Fig. 7 Premature senescence of microglia with greater pseudo-time in AD is associated with gene signatures for inflammatory activation. a UMAP plot colored by microglial pseudo-time trajectory calculated by Monocle3 [71]. b Heatmap showing the relative enrichment of gene co-expression modules differentially expressed with increasing pseudo-time. Module names are colored according to pseudotime progression: Purple, early-; lilac, mid-; yellow, late-pseudotime c Significantly enriched pathway of the co-expression module genes. Pathway names are colored according to plot (b). d Network plot showing hub genes for each module (distinguished by colours) with senescence pathway associated genes highlighted (black circle)
Fig. 7 Premature senescence of microglia with greater pseudo-time in AD is associated with gene signatures for inflammatory activation. a UMAP plot colored by microglial pseudo-time trajectory calculated by Monocle3 [71]. b Heatmap showing the relative enrichment of gene co-expression modules differentially expressed with increasing pseudo-time. Module names are colored according to pseudotime progression: Purple, early-; lilac, mid-; yellow, late-pseudotime c Significantly enriched pathway of the co-expression module genes. Pathway names are colored according to plot (b). d Network plot showing hub genes for each module (distinguished by colours) with senescence pathway associated genes highlighted (black circle)CC BY · PubMed Central

Verification

Claims the paper makes

29 Valid · 2 Not valid · 4 Not checked · 103 Own results and interpretations

76 more claims · 5 with their cited sources checked

Create a free account to see all 138 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 24
  • It may state two separate claims as one. 38
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 48

Metadata

Authors
Fancy, N. N., Smith, A. M., Caramello, A., Tsartsalis, S., Davey, K., Muirhead, R. C. J., McGarry, A., Jenkyns, M. H., Schneegans, E., Chau, V., Thomas, M., Boulger, S., Cheung, T. K. D., Adair, E., Papageorgopoulou, M., Willumsen, N., Khozoie, C., Gomez-Nicola, D., Jackson, J. S., & Matthews, P. M.
Affiliations
  • Hammersmith Hospital (GB)
  • University of Auckland (NZ)
  • University of Geneva (CH)
  • King's College London (GB)
Corresponding author
Matthews, Paul M.
Venue
Acta Neuropathologica
Published
2024-05-02
Volume
147
Issue
1
Pages
78-78
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
OpenAlex
W4396591445
Cited by
48
References
85
Citations by year
2026: 18 · 2025: 20 · 2024: 10
FWCI
13.83
Type
journal article
Language
en
Open access
Licence
Locations
  • Acta Neuropathologica (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ePrints Soton (University of Southampton) (submittedVersion)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
Funders
  • UK Dementia Research Institute
  • Medical Research Council
  • Alzheimer’s Research UK
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
Keywords
Alzheimer's disease, microglia, amyloid-beta, DNA double-strand breaks, mitochondrial dysfunction, endoplasmic reticulum stress, phagocytosis, p16INK4a, senolytics, aging, postmortem brain
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Male, Neuroglia, Amyloid beta-Peptides, Cellular Senescence, Microglia, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.